The possibility of identifying novel biomarkers for neurodegenerative diseases has been greatly enhanced with recent advances in genomics and proteomics. Novel technologies have the potential to hasten the development of new biomarkers useful as predictors of disease etiology and outcome, as well as responsiveness to therapy. Disease-modifying new therapies are very much needed in modern approaches to treatment of neurodegenerative diseases. Current progress in the field encounters a degree of skepticism about the reliability of genomic and proteomic data and its relevance for clinical applications. Standard operating procedures covering sample collection, methodology and statistical analysis need to be fully developed and strictly adhered to in order to assure reproducible and clinically relevant results. Previous studies involving patients with neurodegenerative diseases show promise in using genomic and proteomic approaches for development of new biomarkers. Confirmation of any novel biomarker in multiple independent patient cohorts and correlation of the improvement in biomarker endpoint with clinical improvement in longitudinal patient studies remains crucial for future successful application. We propose that a combination of approaches in biomarker discovery may in the end lead to identification of promising candidates at DNA, RNA, protein and small molecule level.
Introduction
Biomarkers are biological traits which can be measured objectively in peripheral blood, cerebrospinal fluid (CSF) or other biological samples, as well as imaging procedures, and which can be used as indicators of normal or pathological biological processes [1] . Biomarker discovery studies offer clinicians and scientists a novel approach to treating and understanding diseases as they can be invaluable in determining the staging of a disease, classification of disease dissemination, prognosis of disease outcome and monitoring of the clinical treatment [2] . Parkinson's disease, or as tools for discovery of disease-modifying novel therapies are currently much needed [3] . Namely, biomarkers which could be used as surrogate-endpoints in clinical trials, enabling selection of most promising disease-modifying compounds, would prove invaluable [4] . Additionally, disease progression biomarkers would enable administration of appropriate therapy at the 
Novel genomic approaches in predictive medicine
Achievements of the Human Genome Project and the complete decoding of the human genome have opened an unimaginable set of opportunities for scientists to further unveil delicate mechanisms underlying the functional homeostasis of biological systems [5] . Microarrays or gene chips present a powerful tool for high-throughput analysis of transcriptome and have been used extensively in studies aimed at determining biological mechanisms involved in disease onset and progression both in tissues and bodily fluids [6] .
The traditional approach of analyzing affected tissues derived from patients provides a useful insight into disease pathophysiology. However, affected tissues are not always easily accessible, as is the case in neurodegenerative diseases [7] . establishing that these effects are also mirrored in blood [27] . Furthermore, assessing the blood cell count of patients, exclusion of patients with infection and keeping track of therapy the patient is receiving will also reduce the bias which can influence the final results of the studies.
Development of hemogenomic biomarkers in neurology and psychiatry
Several key limitations must be taken into account when performing expression profiling experiments using peripheral blood samples.
The biological variability, namely intraindividual and inter-individual differences, always present a possible problem [28] . The best way to address the problem is to use a large number of samples, divided into a separate training set used to select the biomarker, and preferably several independent test sets, used to validate the biomarker. Additionally, a certain degree of concern regarding technical variability is always 
